EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cardiac safety of chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults

Daniel Rooks iD, Denise P Yates iD, Srikanth Neelakantham, Jens Praestgaard, Ricardo C Cury, Hildo J Lamb iD, Ronenn Roubenoff, Olivier Petricoul, Estelle Lach-Trifilieff, Eric C Svensson

The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · 2573-2582

DOI: 10.1210/clinem/dgag091 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 25.03.2026. Verfasst von Daniel Rooks und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine, Biomedical Research, Novartis, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Myostatin, Antibodies, Monoclonal, Humanized, Activins, Heart. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Biomedical Research, Novartis Translational Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

GLP-1 receptor agonists have revolutionized the treatment of obesity and type 2 diabetes, but may cause excess muscle loss. Inhibitors of the myostatin–activin pathway can cause fat loss and skeletal muscle gain, but the effect of chronic pathway inhibition on human cardiac muscle is not known.

Objective

Investigate the effects of extended inhibition of the myostatin–activin pathway on cardiovascular parameters in healthy older adults.

Design

Randomized, double-blind, placebo-controlled study with 6 months of treatment and up to 6 months of follow-up.

Setting

Single commercial study site Participants 68 healthy community-living men and women aged 60 to 86 years.

Interventions

Intravenous bimagrumab 10 mg/kg or placebo. Main outcome measures Cardiac magnetic resonance assessment of changes in left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF). Changes in total lean body mass (LBM) and total body fat mass (FM) by dual energy X-ray absorptiometry (DXA).

Results

At 6 months, no clinically relevant change was observed in LVMI (least squares mean [90% confidence interval] 1.6 g/m2 [−0.2, 3.4], P = .148) or LVEF (2.0% [−0.4, 4.4], P = .176) between treatments. Total LBM (mean [standard deviation]) increased by 5.5% [3.6], and FM decreased by −14% [8.9] with bimagrumab vs placebo (both P < .001).

Conclusion

Six months of myostatin–activin pathway inhibition with bimagrumab had no effect on cardiac structure or function in healthy older adults compared to placebo. These results support consideration of bimagrumab as a skeletal muscle-sparing intervention in adults undergoing weight loss with GLP-1 receptor agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyostatinAntibodies, Monoclonal, HumanizedActivinsHeartAntibodies, MonoclonalHumansAgedMaleFemaleDouble-Blind MethodAged, 80 and overMiddle AgedSignal TransductionVentricular Function, LeftBody Composition

Stichwörter der Autor:innen

bimagrumabcardiac musclecardiovascular safetymyostatin–activin pathwayolder adult

Substanzen

bimagrumabMyostatinAntibodies, Monoclonal, HumanizedActivinsMSTN protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Translational Medicine, Biomedical Research, Novartis, Cambridge, MA 02139, USA.
  • AQS Statistical Programming, Novartis Healthcare Private Limited, Hyderabad 500081, India.
  • IQS, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
  • Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL 33176, USA.
  • Department of Radiology, Florida International University, Miami, FL 33176, USA.
  • Leiden University Medical Center, Leiden University, Leiden 2311EZ, The Netherlands.

ORCID-Profile: Daniel Rooks, Denise P Yates, Hildo J Lamb

Förderung

  • Novartis Biomedical Research
  • Novartis Translational Medicine

Zitieren

APA

Rooks, D., Yates, D. P., Neelakantham, S., Praestgaard, J., Cury, R. C., Lamb, H. J., Roubenoff, R., Petricoul, O., Lach-Trifilieff, E., & Svensson, E. C. (2026). Cardiac safety of chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults. The Journal of Clinical Endocrinology & Metabolism, 111(9), 2573-2582. https://doi.org/10.1210/clinem/dgag091

Vancouver

Rooks D, Yates DP, Neelakantham S, Praestgaard J, Cury RC, Lamb HJ, et al. Cardiac safety of chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):2573-2582. doi:10.1210/clinem/dgag091

BibTeX
@article{Rooks2026,
  author = {Rooks, Daniel and Yates, Denise P and Neelakantham, Srikanth and Praestgaard, Jens and Cury, Ricardo C and Lamb, Hildo J and Roubenoff, Ronenn and Petricoul, Olivier and Lach-Trifilieff, Estelle and Svensson, Eric C},
  title = {Cardiac safety of chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {9},
  pages = {2573--2582},
  doi = {10.1210/clinem/dgag091}
}
Kostenlos starten →